Use of aminoglycosides as a therapeutic strategy to fight infections caused by Enterobacteriaceae that produce extended-spectrum β-lactamases

• Autor(a) principal: Silva, Júlio Eduardo Barbosa da
• Data de Publicação: 2022
• Outros Autores: Souza, Jaqueline Barbosa de, Macêdo, Daniel Charles dos Santos, Barros, Maria Clara de Sousa Arruda, Campos, Luís André de Almeida, Costa Júnior, Sérgio Dias da, Ferraz Carvalho, Rafaela de Siqueira, Cavalcanti, Isabella Macário Ferro
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Research, Society and Development
• Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/25680
• topic: Infecções bacterianas; β-lactamases de espectro estendido; Enterobactérias; Antibióticos.; Infecciones bacterianas; β-lactamasas de espectro extendido; Enterobacterias; Antibióticos.; Bacterial infections; Extended spectrum β-lactamases; Enterobacteria; Antibiotics.

The treatment of infections caused by enterobacteria that produce extended-spectrum β-lactamases enzymes (ESBLs) is increasingly challenging, so that the indiscriminate and exacerbated use of antibiotics has promoted bacterial resistance and dissemination of these pathogens, making the treatment of these bacteria a public health challenge. Taking into account that aminoglycosides are the antibiotics indicated for the clinical treatment of infections caused by enterobacteria, the objective of this review was to describe the use and effectiveness of aminoglycosides as a therapeutic strategy to combat infections caused by enterobacteria that produce ESBLs. A bibliographic review was carried out through searches in PubMed, Scientific Electronic Library On-line (SCIELO) and Google Scholar databases, selecting articles published between 2011 and 2020, in English, with the following descriptors: Gram-negative bacteria, Resistance and Infections. The results showed that plazomycin is effective against strains of Citrobacter spp., Klebsiella spp. and Enterobacter spp. producing ESBLs, while gentamicin, tobramycin and apramycin are effective against E. coli, Burkholderia spp., Serratia spp., Citrobacter spp., Enterobacter spp. and Klebsiella spp. ESBL producers. Regarding the combination therapy, it can be observed that the combination between two aminoglycosides or between aminoglycosides and other antibiotics promoted a synergistic effect when compared with the monotherapy against E. coli, Enterobacter spp., Enterobacter cloacae and mainly Klebsiella pneumonia producing ESBLs. Therefore, aminoglycosides have shown great potential against this group of bacteria, which represent a great challenge for the medical profession.